IP Library › Granted Patent US 10,287,246
Granted Patent B2
US 10,287,246 · App. 15/890,578 · Granted May 14, 2019

Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms

Inventor: Michael E. Silver (Lake City, MI)
Assignee: The William M. Yarbrough Foundation
C07C331/20A61K9/0014A61K31/145A61K31/198A61K31/26A61K45/06A61K47/34A61K9/06A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,287,246
App. No.
15/890,578
Granted
May 14, 2019
Kind
B2
Abstract

The present invention relates to methods, formulations, and compositions for the treatment of biofilms. In particular, the application discloses isothiocyanate functional surfactants either alone or combination with adjunct agents to treat biofilms. One suitable isothiocyanate functional surfactant is represented by the following chemical structure:

Claims (8)

1. A method, comprising the step of administering to a patient having a biofilm a composition comprising an isothiocyanate functional surfactant, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

2. The method according to claim 1 , wherein the composition comprising the isothiocyanate functional surfactant is administered to the patient at least one of orally, intravenously, intramuscularly, intrathecally, cutaneously, subcutaneously, transdermally, sublingually, buccally, rectally, vaginally, ocularly, otically, and nasally.

3. The method according to claim 1 , wherein the composition comprising the isothiocyanate functional surfactant is topically administered to the patient.

4. The method according to claim 3 , wherein the amount of isothiocyanate functional surfactant in the composition topically administered to the patient ranges from approximately 0.5 nmol/cm2 to approximately 10 μmol/cm2.

5. The method according to claim 4 , wherein the composition comprising the isothiocyanate functional surfactant is a topical preparation selected from the group consisting of ointment, cream, emulsion, lotion and gel.

6. The method according to claim 5 , wherein the composition further comprises one or more pharmaceutical, biological or molecular biological active agents.

7. The method according to claim 6 , wherein the patient is a mammal.

8. The method according to claim 7 , wherein the mammal is a human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2018
From: SILVER, MICHAEL E.
To: THE WILLIAM M YARBROUGH FOUNDATION
Reel/Frame 045937/0589 →
Continuity (8)
Continuation 15786757 · Oct 18, 2017
Continuation In Part 15353260 · Nov 16, 2016
Continuation In Part 15297304 · Oct 19, 2016
Continuation 14594788 · Jan 12, 2015
Continuation 13342516 · Jan 3, 2012
Provisional Application 61502067 · Jun 28, 2011
Provisional Application 61429325 · Jan 3, 2011
Related Publication 20180162811A1 · Jun 14, 2018
Cited By (3)
US 12,239,626 US 12,310,939 US 12,466,789